Euglycemic ketoacidosis following a single dose of empagliflozin

ABSTRACT

Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have recently joined the therapeutic armamentarium for the treatment of diabetes mellitus. SGLT-2 inhibitors, as monotherapy or in combination with other medications, have a favorable effect on hemoglobin A1C concentrations. However, a growing number of reports have described ketoacidosis as a complication following prolonged SGLT-2 inhibitor therapy. We report a case of SGLT-2 inhibitor associated ketoacidosis in a patient following a single first dose of empagliflozin.

KEYWORDS:

• Empagliflozin side-effects
• ketoacidosis
• SGLT-2 inhibitors

Disclosure statement

The authors report no conflict of interest.